Skip to Main Content

University of Toronto spinoff company Interface Biologics Inc. has announced the signing of an evaluation and exclusive license option agreement with Fresenius Medical Care, the world’s largest integrated provider of dialysis products and services. Under the agreement, Fresenius Medical Care will evaluate the use and efficacy of IBI’s EndexoTM technology to various components of Fresenius Medical Cares’ dialysis circuits for treating end-stage renal disease, including dialyzers and blood lines. Following the completion of this evaluation, Fresenius Medical Care can exercise an option to obtain an exclusive, worldwide license to incorporate IBI’s EndexoTM technology in dialysis circuits used for treatment of chronic kidney disease patients in all patient care settings.

Interface Biologics was founded by Professor Paul Santerre, Director of the Institute of Biomaterials and Biomedical Engineering (IBBME), based on his groundbreaking work on improving the biocompatibility of medical implants. The company has hired several U of T graduates, and has Faculty of Medicine professors on its advisory teams, along with Prof. Santerre as Chief Scientific Officer. In July 2005, Interface Biologics moved into Toronto’s MaRS Innovation Centre.

This is Interface Biologics’s third agreement finalized over the past six months; the company’s first products were PICC catheter lines which are now undergoing Food and Drug Administration regulatory procedures and are anticipated to be on the market in early 2011.

Follow the link to read the announcement on Interface Biologics Inc.’s website.

Media Contact

Fahad Pinto
Communications & Media Relations Strategist
416.978.4498